Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S400000, C424S451000, C424S464000, C424S489000
Reexamination Certificate
active
06933310
ABSTRACT:
An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.
REFERENCES:
patent: 4857542 (1989-08-01), Nishi et al.
patent: 5527814 (1996-06-01), Louvel
patent: RE35801 (1998-05-01), Nishi et al.
patent: 2002/0198172 (2002-12-01), Sandage et al.
patent: 208874 (1987-01-01), None
patent: 558861 (1993-09-01), None
patent: 0 633 025 (1995-01-01), None
patent: 5-35128 (1987-05-01), None
patent: 3-215425 (1991-09-01), None
patent: 3-215426 (1991-09-01), None
patent: 5-31523 (1993-05-01), None
patent: 7-25765 (1995-01-01), None
patent: 7-121861 (1995-12-01), None
patent: 9-52801 (1997-02-01), None
patent: 9-52831 (1997-02-01), None
patent: 63-132833 (1998-06-01), None
patent: 10-279480 (1998-10-01), None
patent: 11-79991 (1999-03-01), None
patent: 2906513 (1999-04-01), None
CAS Registry entry for MCI 186.
H. Kawai et al., “Effects of a Novel Free Radical Scavenger, MCI-186, on Ischemic Brain Damage in the Rat Distal Middle Celebral Artery Occlusion Model”, The Journal of Pharmacology and Experimental Therapeutics, vol. 281, No. 2, issued 1997, pp. 921-927.
H. Mitsumoto et al., “Arrest of Motor Neuron Disease in Wobbler Mice Cotreated with CNTF and BDNF”, Science, vol. 265, No. 5175, issued Aug. 1994, pp. 1107-1110.
Yamamoto et al.: “Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia,” Brain Research, vol. 762, No. 1-2, pp. 240-242, (1997) XP-002278046.
K. Kinoshita et al., “Feature: A new treatment for amyotrophic lateral sclerosis (ALS)”, Cranial Nerves, vol. 50, No. 7, pp. 615-624, 1998 with English translation.
K. Ikeda et al., “Brain-derived neurotrophic factor attenuates neuromuscular dysfunction in wobbler mouse motor neuron disease”, Ann. Neurol., 34, 304, 1993.
H. Mitsumoto et al., “The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease”, Ann. Neurol., vol. 36, No. 2, pp. 142-148, Aug. 1994.
H. Mitsumoto et al., “Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF”, Science, vol. 265, pp. 1107-1110, Aug. 1994.
Kishore Gollamudi S.
Mitsubishi Pharma Corporation
Oh Simon J.
LandOfFree
Therapeutic agent for amyotrophic lateral sclerosis (ALS) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for amyotrophic lateral sclerosis (ALS), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for amyotrophic lateral sclerosis (ALS) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504572